Please login to the form below

Not currently logged in
Email:
Password:

Almirall

This page shows the latest Almirall news and features for those working in and with pharma, biotech and healthcare.

Amgen buys Danish partner Nuevolution for $167m

Amgen buys Danish partner Nuevolution for $167m

It will inherit established partnerships that Nuevolution also signed with the likes of Almirall, and Johnson &Johnson, according to the Danish firm’s website, and analysts at Edison said in March ... The Almirall partnership includes a RORγt

Latest news

More from news
Approximately 9 fully matching, plus 65 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    12. Symatese. Almirall. Development collaboration. Customised products in aesthetics. 8. AgaImmune.

  • Deal Watch December 2016 Deal Watch December 2016

    510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... $21m plus $80m equity. Biosimilars. Nuevolution. Almirall. $453m. $11.8m. Inhibitors to transcription

  • Deal Watch October 2016 Deal Watch October 2016

    $575m. $198m. 2.9. Respiratory 2014. Almirall. Products pipeline. $2, 100 milestones.

  • Deal Watch July 2016 Deal Watch July 2016

    Celyad. $311m. $12.5m. Almirall. Patagonia. $28m. $3.5m. Petra Pharma. Sprint BioScience. ... Almirall's initial expenditure has been a more modest $3.5m for this earlier stage product.

  • Stronger together Stronger together

    Also speaking at the eyeforpharma conference was Almirall's CEO Eduardo Sanchiz, who noted that, while patient-centricity is often talked about in the industry, “we have difficulties putting it in

More from intelligence
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 5 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics